Blonanserin (Lonasen) is a relatively new atypical antipsychotic (approved by PMDA in January 2008) commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As with many second-generation (atypical) antipsychotics it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics such as haloperidol.

CAS：132810-10-7
中文别名：布南瑟林;2-(4-乙基-1-哌嗪基)-4-(4-氟苯基)-5,6,7,8,9,10-六氢环辛[b]吡啶;布兰色林;
英文别名：2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine;2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine;
分子式：C23H30FN3
分子量：367.503
精确质量：367.242
Psa：19.37
Logp：4.6915

UNII：AQ316B4F8C

密度：1.095 g/cm3
沸点：540.8ºC at 760mmHg
闪点：280.9ºC
折射率：1.557
蒸汽压：9.21E-12mmHg at 25°C

用途
精神分裂症治疗药